Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to AcalabrutinibLiver Published on 2024-06-202024-09-05 Journal: ACG Case Reports Journal [Category] update2024, [키워드] Acalabrutinib cholestatic hepatitis hepatitis B Hepatitis B reactivation tyrosine kinase inhibitor [DOI] 10.14309/crj.0000000000001387 PMC 바로가기 [Article Type] Liver
Viral Infections and Incidence of Reactivations in Chronic Myeloid Leukemia PatientsReview Published on 2023-10-172024-09-04 Journal: Oncology [Category] 대상포진, [키워드] chronic myeloid leukemia Reactivation tyrosine kinase inhibitor viral infections [DOI] 10.1159/000534266 PMC 바로가기 [Article Type] Review
Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitorsComparative Study Published on 2023-04-012023-06-12 Journal: Hepatology international [Category] B형 간염, [키워드] antiviral therapy hepatitis B surface antigen Hepatitis B virus Hepatocellular carcinoma Immunotherapy Median survival time Prognosis Programmed cell death protein-1 inhibitor Reactivation tyrosine kinase inhibitor [DOI] 10.1007/s12072-022-10450-4 [Article Type] Comparative Study
Potential interactions between antineoplastic agents and medicines used to treat Covid-19Article Published on 2022-12-012022-11-15 Journal: Journal of Oncology Pharmacy Practice [Category] 치료제, [키워드] accounted Affect antineoplastic agents antineoplastic drug Baricitinib benefit Cancer Chloroquine Combination conducted COVID-19 disease drug drug combinations drug-drug interaction Drug-drug interactions Drug–drug interactions drug–drug interactions. Health Hydroxychloroquine identify Interaction interaction effect interactions involved Lexicomp Medicine Modification outcomes Patient Patients with cancer pharmacokinetic pharmacological intervention plasma concentration Potential professional risk severity therapeutic treat Treatment tyrosine kinase inhibitor was increased [DOI] 10.1177/10781552211040494 PMC 바로가기
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies혈액암이 있는 성인 환자의 SARS-CoV-2 백신 1차 및 2차 접종에 대한 면역 반응의 체계적인 검토 및 메타 분석Review Published on 2022-09-012022-09-11 Journal: International immunopharmacology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 95% confidence interval 95%CI affected affecting anti-CD20 therapy antibody Antibody detection Antibody Response article booster dose booster doses calculated Cancer patients chronic lymphocytic leukemia CLL Complete conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines develop Diagnosis disease doses evaluate first dose Google Google Scholar healthy subject healthy subjects Hematological malignancies Hematological malignancy higher risk highlight highlighting immune response Immunity immunization Immunocompromised immunogenicity immunosuppressive IMPROVE kinase inhibitors less leukemia lowest Lymphocytic leukemia lymphoma malignancy measure Meta-analysis mRNA mRNA-1273 Myeloma Patient Primary outcome response rate SARS-CoV-2 SARS-CoV-2 vaccine second dose secondary outcome Secondary outcomes seropositive Seropositivity severe coronavirus disease solid tumor solid tumors status subgroup subtype systematic review the disease the vaccine tumors tyrosine tyrosine kinase inhibitor tyrosine kinase inhibitors Vaccine vaccine dose vaccine's immunogenicity Web of Science [DOI] 10.1016/j.intimp.2022.109046 PMC 바로가기 [Article Type] Review
The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19INVENT COVID 시험: COVID-19에 의해 유발된 급성 호흡곤란 증후군이 있는 피험자를 대상으로 정맥 이마티닙 메실레이트(Impentri®)의 효능과 안전성을 조사하는 무작위 대조 시험을 위한 구조화된 프로토콜Study Protocol Published on 2022-02-162022-09-10 Journal: Trials [Category] COVID19(2023년), MERS, SARS, 임상, [키워드] 1:1 28-day mortality acute respiratory distress acute respiratory distress syndrome Admission ARDS Berlin criteria bis in die Chain Reaction changes in characterized clinical trial coronavirus disease Coronavirus disease 2019 COVID COVID-19 death decrease demonstrated discharge disease severity double-blind edema Efficacy and safety endothelial Endothelial dysfunction Estimated Extravascular lung water hypoxemic Hypoxemic respiratory failure ICU Imatinib imatinib mesylate immune response include increase in index Inflammation inflammatory conditions inhibitor intensive care intensive care unit intravenous Invasive mechanical ventilation IV infusion Kinase inhibitor life-threatening lung Lungs mechanical ventilation mechanically ventilated mesylate moderate-severe Mortality multicenter Older outcome Oxygenation pandemic parallel-group parameter parameters participant pharmacokinetics Placebo placebo-controlled polymerase chain polymerase chain reaction positive Prevent protocol Pulmonary edema randomization Randomized Randomized controlled trial recruitment reduce reduction in reflected respiratory distress Respiratory failure SARS-CoV2 secondary study period subject syndrome therapy Tolerability Trial registration tyrosine tyrosine kinase inhibitor Vascular vascular permeability Ventilation ventilator-free day Ventilator-free days water widespread [DOI] 10.1186/s13063-022-06055-9 PMC 바로가기 [Article Type] Study Protocol
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study항암제 치료 클래스는 암 환자에서 COVID-19 mRNA-BNT162b2 백신 면역원성을 조절합니다: 전향적 Vax-On 연구의 2차 분석Article Published on 2022-02-012022-09-12 Journal: ESMO open [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] accounted Analysis antibody Antibody Response Antineoplastic Cancer cancer treatment carried Chemotherapy classification Cooperative correlated correlation Corticosteroid COVID-19 COVID-19 vaccination COVID-19 vaccine Cytotoxic chemotherapy defined DNA dose drug Effect enrolled granulocyte group humoral IgG Immunoglobulin immunosuppressive inhibitor inhibitors Interaction intravesical lack modulate mTOR inhibitor Patient performance status predicted Rapamycin Receptor binding domain reduced retained second dose Seroconversion seroconversion response significantly significantly lower Specific Spike protein subgroup subgroup analysis subgroups targeted therapy the S1 subunit the SARS-CoV-2 therapy TKI TKIs treated Treatment tyrosine kinase inhibitor Vaccine vaccine immunogenicity Variation [DOI] 10.1016/j.esmoop.2021.100350 PMC 바로가기 [Article Type] Article
PET/CT variants and pitfalls in malignant melanoma악성 흑색종의 PET/CT 변이체 및 함정Review Published on 2022-01-042022-09-11 Journal: Cancer Imaging [Category] SARS, 변종, 치료기술, [키워드] adverse event Algorithms Cancer Community confirmation COVID 19 COVID19 described detect diagnostic digital PET disease False-positive FDG focus immune activation Immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy IMPROVE include increasingly indication indications induce Interpretation irAEs kinase inhibitors learning curve lesions limitations Malignant melanoma Melanoma pandemic patients pet PET technology PET/CT Pitfalls, variants protocol released staging Therapies tyrosine tyrosine kinase inhibitor tyrosine kinase inhibitors variant variants [DOI] 10.1186/s40644-021-00440-4 PMC 바로가기 [Article Type] Review
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective studySARS-CoV-2에 대한 백신 접종 후 WM 환자 106명의 중화 항체 반응 불량: 전향적 연구Clinical Trial Published on 2021-11-092022-09-12 Journal: Blood advances [Category] MERS, SARS, 임상, 진단, [키워드] Antibody Response AZD1222 BNT162b2 Comparisons Control COVID-19 COVID-19 vaccination dose drug enrolled enzyme-linked immunosorbent evaluate evaluated food General population healthy control Hematologic malignancy higher risk humoral immune dysregulation independent infection control involved Measures median age methodology NAb NAbs neutralizing antibody Neutralizing antibody response outcome Patient Poor Prognostic factor Prospective Study Registered SARS-CoV-2 severe complication susceptible therapy-related immunosuppression Treatment tyrosine kinase inhibitor vaccination Vaccine [DOI] 10.1182/bloodadvances.2021005444 PMC 바로가기 [Article Type] Clinical Trial
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology폐암 모델, 중증 급성 호흡기 증후군 공개Article Published on 2021-11-012022-09-11 Journal: International Journal of Molecular Sciences [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] ACE2 ACE2 expression acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition AXL bemcentinib bronchial organoids cancer cell lines caused Cell cell surface component coronavirus coronavirus disease Coronavirus disease 2019 Effects EGFR EMT epithelial cells expression growth healthy highlight host cell host cells increasingly induce infected cell infected cells infection with SARS-CoV-2 Infectious disease inhibitor investigated Kinase inhibitor lung cancer Model model system morbidity morbidity and mortality nasal epithelium NSCLC observation occur offer other respiratory virus Other respiratory viruses overexpression Pathogenesis pathogenesis of SARS-CoV-2 Patient Patients with cancer potential mechanism potential mechanisms reduction Regulation repressed respiratory respiratory distress Respiratory distress syndrome respiratory tracts respiratory viruses resulting SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pathogenesis SARS-CoV-2 receptor severe acute respiratory syndrome Coronavirus surface protein the cell tight junction tissue tissues TMPRSS2 transcriptional transcriptional change transforming growth factor transition tyrosine tyrosine kinase inhibitor up-regulation variety viruses ZEB1 ZEB1. [DOI] 10.1016/j.jtho.2021.07.002 PMC 바로가기 [Article Type] Article